426 related articles for article (PubMed ID: 18062627)
21. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.
Koppelmans V; Breteler MM; Boogerd W; Seynaeve C; Gundy C; Schagen SB
J Clin Oncol; 2012 Apr; 30(10):1080-6. PubMed ID: 22370315
[TBL] [Abstract][Full Text] [Related]
22. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
[TBL] [Abstract][Full Text] [Related]
23. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
Semiglasov VF; Stepula VV; Dudov A; Lehmacher W; Mengs U
Anticancer Res; 2004; 24(2C):1293-302. PubMed ID: 15154663
[TBL] [Abstract][Full Text] [Related]
24. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
25. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
[TBL] [Abstract][Full Text] [Related]
26. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Yu TK; Whitman GJ; Thames HD; Buzdar AU; Strom EA; Perkins GH; Schechter NR; McNeese MD; Kau SW; Thomas ES; Hortobagyi GN; Buchholz TA
J Natl Cancer Inst; 2004 Nov; 96(22):1676-81. PubMed ID: 15547180
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.
Zachariae R; Paulsen K; Mehlsen M; Jensen AB; Johansson A; von der Maase H
Psychother Psychosom; 2007; 76(6):376-84. PubMed ID: 17917474
[TBL] [Abstract][Full Text] [Related]
28. Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial.
Irwin LE; Chlebowski RT; Weiner JM; Reynolds R; Pugh RP; Ryden VM; Bateman JR
Cancer Treat Rep; 1980; 64(8-9):981-4. PubMed ID: 7004635
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
[TBL] [Abstract][Full Text] [Related]
30. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
31. [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Ishida T; Kusaba T; Hayakawa H
Gan To Kagaku Ryoho; 2002 May; 29(5):723-8. PubMed ID: 12040676
[TBL] [Abstract][Full Text] [Related]
32. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113
[TBL] [Abstract][Full Text] [Related]
33. [Toxicity of doxorubicin and cyclophosphamide (60 mg/600 mg/m2) in adjuvant chemotherapy for breast cancer].
Tsutani Y; Saeki T; Aogi K; Ohsumi S; Takashima S
Gan To Kagaku Ryoho; 2005 Jun; 32(6):809-13. PubMed ID: 15984521
[TBL] [Abstract][Full Text] [Related]
34. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
35. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
Partridge A; Gelber S; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Winer E
Eur J Cancer; 2007 Jul; 43(11):1646-53. PubMed ID: 17512721
[TBL] [Abstract][Full Text] [Related]
36. DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients.
Ejlertsen B; Jensen MB; Mouridsen HT; Andersen J; Cold S; Jakobsen E; Kamby C; Sørensen PG; Ewertz M
Acta Oncol; 2008; 47(4):709-17. PubMed ID: 18465339
[TBL] [Abstract][Full Text] [Related]
37. [Prognostication of hematotoxicity for radio- and chemotherapy in patients with breast cancer].
Ivanov SD; Iamshanov VA; Korytova LI; Khazova TV; Arzumanov AS
Vopr Onkol; 2003; 49(5):601-7. PubMed ID: 14682132
[TBL] [Abstract][Full Text] [Related]
38. Feasibilty of a sleep intervention during adjuvant breast cancer chemotherapy.
Berger AM; VonEssen S; Khun BR; Piper BF; Farr L; Agrawal S; Lynch JC; Higginbotham P
Oncol Nurs Forum; 2002; 29(10):1431-41. PubMed ID: 12432414
[TBL] [Abstract][Full Text] [Related]
39. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
[TBL] [Abstract][Full Text] [Related]
40. Level of fatigue in women receiving dose-dense versus standard chemotherapy for breast cancer: a pilot study.
Sura W; Murphy SO; Gonzales I
Oncol Nurs Forum; 2006 Sep; 33(5):1015-21. PubMed ID: 16955128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]